Technology
Health
Biotechnology

Co-Diagnostics

$1.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.67%) Today
+$0.02 (1.69%) After Hours

Why Robinhood?

You can buy or sell Co-Diagnostics and other stocks, options, ETFs, and crypto commission-free!

About

Co-Diagnostics, Inc. Common Stock, also called Co-Diagnostics, is a molecular diagnostics company, which develops, manufactures and markets diagnostics technology. Read More It intends to manufacture and sell reagents used for diagnostic tests that function via the detection and analysis of nucleic acid molecules, and to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded by Brent Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Employees
17
Headquarters
Salt Lake City, Utah
Founded
2013
Market Cap
15.20M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
494.44K
High Today
$1.22
Low Today
$1.16
Open Price
$1.20
Volume
146.41K
52 Week High
$6.66
52 Week Low
$0.90

Collections

Technology
Health
Biotechnology
2017 IPO
US
North America

News

Associated PressMar 14

Co-Diagnostics, Inc. to Host 1st Semiannual Distributor Conference on March 26-28

SALT LAKE CITY--(BUSINESS WIRE)--Mar 14, 2019--Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting its 1 st semiannual distributor conference on March 26-28 at the Company’s headquarters in Salt Lake City, Utah. Conference attendees already committed to attend include government, environmental testing, and private laboratory customers and distributors of the Company’s...

66
MarketBeatMar 11

Stock Price, News, & Analysis for Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah. MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX) Community Ranking: 2.5 out of 5 ( ) Outperform Votes: 141 (Vote ...

5
Associated PressMar 7

Co-Diagnostics, Inc. Receives CE Mark for Zika/Dengue/Chikungunya Multiplex Test

SALT LAKE CITY--(BUSINESS WIRE)--Mar 7, 2019--Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ZDC Test has obtained CE mark regulatory clearance to be sold as an in vitro diagnostic (“IVD”) for the diagnosis of Zika, dengue, and chikungunya in accepting markets, and is now available for purchase from the Company’s Utah-based ISO-13485 facility. The Declaration of Co...

262

Earnings

-$0.33
-$0.26
-$0.18
-$0.11
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.